Endomedix, Inc. has announced it has secured $4.6 million in a recent funding round from investors. The medical device venture is developing a tunable polysaccharide platform capable of producing a family of new biomaterials. Its flagship product, PlexiClot™ Absorbable Hemostat, is designed to control bleeding specifically in brain and spinal surgeries, addressing a critical need within a $1.9 billion market.
PlexiClot introduces a fundamental innovation in bleeding control for these procedures, representing the first significant advancement since the current standard of care was established in 1945. The device operates on new mechanisms of action, moving beyond reliance on biochemical thrombin action and manual pressure. This innovation aims to eliminate a documented cause of reoperations linked to existing devices, potentially saving hospitals substantial unreimbursed costs associated with complications, lengthy stays, and readmissions. Its performance has been confirmed in three large animal trials.
The newly raised capital will be instrumental as Endomedix plans to scale up production of PlexiClot. The company's composition of matter, method of manufacture, and mechanisms of action are protected by eight issued patents, with key protections extending to 2038. The Endomedix team is led by medical device veteran Richard Russo, with R&D overseen by Piyush Modak. The program has attracted significant interest and support from the medical community, evidenced by 18 neurosurgeons and physicians investing in the company.
This investment positions Endomedix to advance PlexiClot towards becoming the first device approved by the FDA specifically for brain surgery. The company plans to leverage this funding to drive its growth initiatives, prepare for regulatory milestones, and ultimately bring its innovative solution to market, aiming to establish a new standard of care in neurosurgical bleeding control. The sector is also noted for high M&A activity, often occurring prior to final FDA approval.
